ALGS ALGS
Company Profile ↓Company Overview
ALGS (ALGS) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $2.19M (-39.5% YoY); net profit $-24.19M.
- Trailing 12 Months Year-on-year growth — revenue -39.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -39.46% |
Stock Price Performance
| 1 Year: | -40.75% |
| 6 Months: | -36.97% |
| 3 Months: | -25.35% |
| 1 Month: | -22.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.73 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 64.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 140.00K | 4.29M | 1.08M | 694.00K | 1.06M | 1.25M | 311.00K | 965.00K | 741.00K | 2.83M |
| Operating Income | -14.50M | -20.72M | -21.27M | -21.56M | -27.74M | -29.57M | -33.07M | -35.56M | -20.39M | -18.95M | -23.92M | -19.14M | -19.07M | -22.05M | -26.41M | -20.13M | -19.24M | -18.57M | -28.36M | -26.93M |
| Net Income | -14.05M | -20.03M | -20.80M | -33.30M | -27.67M | -29.82M | -33.12M | -35.62M | -19.92M | -18.62M | -22.95M | -18.79M | -18.04M | -34.86M | 5.06M | -19.26M | 43.09M | -15.86M | -31.54M | -23.04M |
| Diluted EPS | - | - | - | - | - | - | -0.78 | -0.84 | -0.47 | -0.44 | -0.53 | -0.43 | -10.37 | -5.58 | 0.81 | -3.07 | -2.11 | -1.53 | -3.04 | -2.21 |
| R&D Expense | 11.73M | 17.30M | 17.18M | 17.33M | 22.87M | 24.55M | 28.13M | 31.68M | 16.51M | 17.79M | 18.14M | 16.78M | 15.87M | 16.37M | 21.10M | 16.77M | 14.50M | 13.98M | 23.94M | 23.35M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 6.19M | 3.61M | 2.19M |
| Operating Income | -54.04M | -97.83M | -128.32M | -97.58M | -88.13M | -89.15M | -87.98M |
| Net Income | -52.26M | -108.54M | -128.33M | -96.05M | -87.68M | -131.21M | -24.19M |
| Diluted EPS | - | - | - | -2.25 | -34.20 | -20.94 | -2.45 |
| R&D Expense | 44.04M | 79.89M | 104.15M | 85.08M | 73.04M | 70.27M | 69.45M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 146.52M | 265.30M | 235.37M | 146.69M | 151.53M | 70.09M | 88.53M |
| Total Equity | -13.75M | -64.89M | 220.04M | 184.73M | 103.90M | 92.08M | -28.97M | 53.55M |
| Cash & Equivalents | - | 69.56M | 220.38M | 186.82M | 81.35M | 135.70M | 37.00M | 18.30M |
| Total Liabilities | - | 29.33M | 45.26M | 50.64M | 42.79M | 59.45M | 99.07M | 34.99M |
| Current Liabilities | - | 13.82M | 30.27M | 38.96M | 33.13M | 23.91M | 21.74M | 21.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -46.77M | -74.26M | -115.66M | -79.39M | -79.00M | -80.74M | -82.50M |
| Investing Cash Flow | 6.79M | 32.76M | 3.02M | -26.29M | 44.98M | -18.28M | -37.83M |
| Financing Cash Flow | 85.53M | 192.35M | 78.68M | 164.00K | 88.33M | 355.00K | 101.64M |
| Capital Expenditure | -2.79M | -2.06M | -892.00K | -943.00K | -19.00K | -130.00K | - |
| Free Cash Flow | -49.55M | -76.33M | -116.55M | -80.33M | -79.02M | -80.87M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -1,423.5% | -2,469.0% | -4,024.9% |
| Net Margin % | - | - | - | - | -1,416.2% | -3,633.6% | -1,106.7% |
| ROE % | 80.5% | -49.3% | -69.5% | -92.4% | -95.2% | 452.9% | -45.2% |
| ROCE % | -40.7% | -41.6% | -65.3% | -85.9% | -69.1% | -184.4% | -130.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALGS
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPU0VkdDUtZmMwajcwSkNrTmlUY3dpZHdTRVBmLVdmWE1xOHY0NXI1Wm5aYk9zN3ZmNnhmbXBYOVV0UXdNNlpWNjFKWlNnQTVJeUJaOVdFMWJnR0N0YnNXZ2t5amJjZDlPNEtMQmtuTUxyZm8wWmtlQnZzMllfcWdXNk1SaHlKOVJnWnhqYm…
Aligos Therapeutics to report results before markets open Aug. 6 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPRWloRDlPajIxYXlZcWVGb2FkTXJvZU1HRDVjWHM4OWN1emoxZC11a2V4LU9KTDkwaDMwejRHV1dPOFlZV0pzNzlKUmpQa2FrdVJ5NFkwb0VYTWdFbFY1RG8wS01pck53MDJZVjZfbFo0a1JicEZsTGdrVi03N1lYRzJMeFBQSzhFTmZlT3…
Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOamVpVUtMLXUxN3ZhSFhKYjBaTjFtZ0V2NkNVdjlCdzhTUUNuWW5seWIwbU5HcXAtaTFqUHVjUUpIM1kxcUt0WXBiSHdZV21HMm56N1EwQk9LbUlDS25hTERuYnB3eEEyZ3hOdGx3elNBUGR0MUwxT1RQVC02ZURvaXJyRDEyZXpTeC12QX…
Jefferies reiterates Aligos Therapeutics stock rating on China deal - Investing.com
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPVV9sZDVuRmZPUF9iRW5mNTJ0ampHZjA0VGxoMjRZVzBUQlE0a0pEOTNPUDJkVzNmOGtJcUY0LXNtNlY0b2pjckVrTncxMVdRbXJ2UzZDLXVON2Rrc3pIU1N2V2RGMEFXNEp3dFRkbU1VYmZfUkxqLUpUTGd0MGczZk0wWlcxZ0h3TU1yRl…
Avoiding Lag: Real-Time Signals in (ALGS) Movement - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQUWxPVUk0REpFV01HY0hwYnVhYW5wbWR2X3pJSk1nU25pdFBZNjEtWlRvMmJnd1JMUzB3UFlvU2pwOEFHbldqTVNmT2stdndEeks5cVk1QU42ajhvUWtYczdWdk1aSWg0WU42VEhvMkRxMlFaTEpXRXMwTE5CNHFHbE5TVS1CaTlzY3hYQz…
Aligos Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALGS) - TradingView
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOeWJRV2JWT3FQdEVYbHNBWUd6dWtUQVl3R1JPQVpXQVMzX0lvcEs0MXl3ZW9ndkpmM3BOTmRabVJOWHg3VUtZXzdsc2N4RjlKVUZ0VXBxMFhrLWdISngtRDBVcUU2ZlVIMDBVT093QXVIY0RMMTZ4bW94dE43a2JfZ3FnMVJFdw?oc=5" t…
ALGS — Frequently Asked Questions
What is the current share price of ALGS?
As of 2026-08-05 17:25 PDT, ALGS trades at $4.74 on NASDAQ/NYSE. Its 52-week range is $4.08 to $13.30.
What is the P/E ratio of ALGS?
ALGS trades at a trailing price-to-earnings (P/E) ratio of -1.93.
What is the return on equity (ROE) of ALGS?
ALGS has a return on equity (ROE) of -45.18%. Its return on capital employed (ROCE) is -130.74%.
Is ALGS a good stock to buy?
This page provides a data-driven analysis of ALGS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.